The Scottish Medicines Consortium is a committee of clinicians, pharmacists, NHS board representatives, the pharmaceutical industry and the public.
The purpose of this committee is to decide which medicines should be accepted for use by NHSScotland.
The committee meets once a month. Below are the decisions that have been taken this month.
|10/09/2018||Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy)|
|10/09/2018||Pembrolizumab (Keytruda) (urothelial carcinoma)|
|10/09/2018||Dolutegravir rilpivirine (Juluca)|
For more information on the decisions have a look at the Scottish Medicines Consortium website here.